P2P review · IL-12/23 inhibitor
Ustekinumab (Stelara) P2P review prep
IL-12/23 inhibitor. Indications: Psoriasis, PsA, Crohn's, UC
Drug class
IL-12/23 inhibitor
Payer criteria typically applied
- Anti-TNF failure
- Disease severity
Common medical director objections
- Anti-TNF failure required by formulary
Pitfalls to avoid
- Step therapy through TNFi
Frequently asked questions
What does the payer typically require for Ustekinumab (Stelara)?
Anti-TNF failure; Disease severity.
What objections does the medical director typically raise?
Anti-TNF failure required by formulary.
What pitfalls should I avoid during the P2P call?
Step therapy through TNFi.
Sources
Prep Ustekinumab (Stelara) P2Ps faster — try ApprovalHelp free
ApprovalHelp auto-prepares P2P talking points from the patient's chart, surfaces payer-specific objections, and generates the post-call appeal draft. no setup fee.
Get started →Contact: hello@approvalhelp.com